Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
CagriSema vs Retatrutide is one of the most important next-generation obesity peptide comparisons going into 2026
Serious side effects are rare but can include gallstones and pancreatitis
Although they havent been officially approved for other treatments, the semaglutides in Ozempic and Wegovy have shown a variety of other health benefits
Dietary Determinants of Plasma Homocysteine Concentrations. Seminars in Vascular Medicine, vol
US$ 25.94
US$ 22.91
US$ 28.26
US$ 21.46
US$ 25.98
US$ 20.24
US$ 26.72
